



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Inga Reynisdottir, Jeffrey R. Gulcher, Struan F. Grant and Gudmar Thorleifsson

Application No.: 10/533,365 Group: 1634

371(c) Date: November 9, 2005 Examiner: Switzer, J.C.

Confirmation No.: 4456

For: HUMAN TYPE II DIABETES GENE-SLIT-3 LOCATED ON CHROMOSOME 5q35

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
<u>7/29/08</u>	<u>Katie Norris</u>
Date	Signature
<u>Katie Norris</u>	
Typed or printed name of person signing certificate	

**REPLY TO RESTRICTION REQUIREMENT
AND PRELIMINARY AMENDMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Responsive to the Restriction Requirement dated May 16, 2008, the claims of Group I, (Claims 1, 3, 6, 27-30, 36-42, and 44-48) drawn to a method of diagnosing a susceptibility to type II diabetes comprising detecting a polymorphism in a SLIT-3 nucleic acid and methods for detecting SLIT-3 nucleic acids, are elected for prosecution. Applicants reserve the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions. Applicants do not hereby abandon or waive any rights in the non-elected inventions.

Responsive to the requirement for an election of species for searching purposes, Applicants hereby elect marker DG5S881 as the species. The sequence relating to marker

DG5S881 is shown in Fig. 12 as SEQ ID NO: 227. Claims readable on the elected species are 1, 3, 27, 28, 29, 45, 46, 47 and 48.

Please amend the application as follows: